Module

State-of-the-Art Management of Waldenström’s Macroglobulinemia

Source: Promising Directions in Myeloma and Lymphoproliferative Disorders: Approaching Resistance, Retreatment, and Maintenance Through Novel Clinical Pathways

State-of-the-Art Management of Waldenström’s Macroglobulinemia


Faculty:

  • Steven P. Treon, MD, MA, PhD

CME CREDIT INFORMATION

Release Date: 04/22/08

Expiration Date: 04/21/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Registered Nurses: 0.8 Nursing CE credit

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the role of mast cells in Waldenström’s macroglobulinemia and the potential for agents targeting these cells
  • Recall data concerning the combination of targeted therapies with chemotherapy for upfront and salvage treatment of Waldenström’s macroglobulinemia
  • Summarize the data about agents being studied for the prevention of Waldenström’s macroglobulinemia
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grants provided by:

Educational grants support only the CME-certified components of this program.